Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vistin Pharma Call Transcript 2024

Feb 9, 2024

3782_rns_2024-02-09_b220be73-b058-4432-bf21-454d6bb1f162.html

Call Transcript

Open in viewer

Opens in your device viewer

Vistin Pharma ASA: Invitation to Q4 2023 conference call

Vistin Pharma ASA: Invitation to Q4 2023 conference call

Oslo, Norway, 9 February 2024

Vistin Pharma ASA will release its fourth quarter and preliminary 2023 results

on Friday 16(th) of February 2024. Vistin Pharma will host a conference call for

all shareholders and interested parties at the same day; Friday 16(th) of

February at 08:30 CET. There will be a Q&A session following the management

discussion.

The conference call will be held in English.

The fourth quarter conference call will be available via web and audio through

the following access points:

Webcast:

https://edge.media-server.com/mmc/p/zfievj3m

Telephone conference (online registration):

https://register.vevent.com/register/BI4f66989ce55146f7ba76754c37cdec44

*****

For further information, please contact:

Alexander Karlsen

CFO

+47 97053621

[email protected]

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin

Hydrochloride (API). The Metformin is also available as Direct Compressible

lubricated granules. As a solely dedicated European Metformin producer, Vistin

Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin

Pharma is headquartered in Oslo, Norway, and has highly qualified employees and

a dedicated manufacturing facility in Kragerø.